Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcus Biosciences Inc.

16.64
+2.0413.97%
Post-market: 16.690.0500+0.30%19:42 EDT
Volume:1.88M
Turnover:30.63M
Market Cap:1.77B
PE:-5.41
High:17.19
Open:15.80
Low:15.09
Close:14.60
52wk High:18.98
52wk Low:6.50
Shares:106.43M
Float Shares:59.89M
Volume Ratio:1.36
T/O Rate:3.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0737
EPS(LYR):-3.1410
ROE:-50.34%
ROA:-18.69%
PB:3.23
PE(LYR):-5.30

Loading ...

Arcus Biosciences Is Maintained at Buy by Citigroup

Dow Jones
·
9 hours ago

Sector Update: Health Care Stocks Higher Premarket Monday

MT Newswires Live
·
Yesterday

Gilead Announces Promising Phase 3 Results for Trodelvy in First-Line Metastatic Triple-Negative Breast Cancer and New Data on Domvanalimab Combination in Gastric and Esophageal Cancer

Reuters
·
Yesterday

Arcus announces first OS results from Arm A1 of Phase 2 EDGE-Gastric study

TIPRANKS
·
Yesterday

BRIEF-Arcus Bioscience Announces First Overall Survival Results From Phase 2 Edge-Gastric Study

Reuters
·
Yesterday

Anti-Tigit Domvanalimab Plus Anti-Pd-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 Edge-Gastric Study

THOMSON REUTERS
·
Yesterday

Arcus Biosciences Inc - No Unexpected Safety Signals Observed in Study

THOMSON REUTERS
·
Yesterday

Arcus Biosciences reports 267 month median overall survival with domvanalimab zimberelimab and chemotherapy in phase 2 gastric cancer study

Reuters
·
Yesterday

Arcus Biosciences Announces New Equity Compensation Grants for Employees

Reuters
·
Oct 10

Arcus Biosciences Inc. COO Jennifer Jarrett Reports Disposal of Common Shares

Reuters
·
Oct 09

Arcus Biosciences (RCUS) Gets a Buy from Cantor Fitzgerald

TIPRANKS
·
Oct 08

Arcus Biosciences Price Target Raised to $39.00/Share From $32.00 by Truist Securities

Dow Jones
·
Oct 07

Arcus Biosciences price target raised to $39 from $32 at Truist

TIPRANKS
·
Oct 07

Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating

MT Newswires Live
·
Oct 07

Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (SENS) and Arcus Biosciences (RCUS)

TIPRANKS
·
Oct 07

Why Is Arcus Biosciences Stock Trading Higher On Monday?

Benzinga_recent_news
·
Oct 07

Arcus Biosciences Up Over 15%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk

Dow Jones
·
Oct 06

Truist says Arcus Biosciences data for Casdatifan ‘looks like a home run’

TIPRANKS
·
Oct 06

Arcus Biosciences Inc - Casdatifan Data Better on All Efficacy Measures in Phase 1/1B ARC-20 Study

THOMSON REUTERS
·
Oct 06

Arcus Biosciences- Median Progression-Free Survival Was 12.2 Months, 18-Month Landmark Pfs Was 43% in Pooled Analysis of All Four Monotherapy Cohorts

THOMSON REUTERS
·
Oct 06